Start-up
ONCOdianova GmbH
ONCOdianova – The Future of Biomarkers
About Oncodianova
ONCOdianova‘s antibody development program concentrates on the tissue-based detection of cancer immunology checkpoint biomarkers. Our vision is to provide the best primary antibodies for combined use in multiplex IHC panels.
Multiplex antibody IHC assay will allow to carefully identify what cell expresses the target, not just whether the target is present. The complexities of inhibitory immune checkpoint pathways along with the interplay of the tumor cells, the microenvironment and systemic immune parameters offer opportunities for research and clinical translation into immunotherapy. We believe that IHC-assessment of predictive immune checkpoint targets in tumor tissues will be crucial and indispensable to select patients and differentiating drugs to optimal guide treatment by immunotherapy.
- Founding: 2018
- Focus : Service
- Industry : Biotechnology
Product portfolio of Oncodianova
Here you will find ONCOdianova GmbH
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous